{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T10:19:33Z","timestamp":1771669173807,"version":"3.50.1"},"update-to":[{"DOI":"10.1371\/journal.pntd.0009636","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T00:00:00Z","timestamp":1628121600000}}],"reference-count":37,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T00:00:00Z","timestamp":1627257600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:p>Nontuberculosis mycobacterial (NTM) infections are increasing in prevalence across the world. In many cases, treatment options for these infections are limited. However, there has been progress in recent years in the development of new antimycobacterial drugs. Here, we investigate the <jats:italic>in vitro<\/jats:italic> activity of SPR719, a novel aminobenzimidazole antibiotic and the active form of the clinical-stage compound, SPR720, against several isolates of <jats:italic>Mycobacterium ulcerans<\/jats:italic>, <jats:italic>Mycobacterium marinum<\/jats:italic> and <jats:italic>Mycobacterium chimaera<\/jats:italic>. We show that SPR719 is active against these NTM species with a MIC range of 0.125\u20134 \u03bcg\/ml and that this compares favorably with the commonly utilized antimycobacterial antibiotics, rifampicin and clarithromycin. Our findings suggest that SPR720 should be further evaluated for the treatment of NTM infections.<\/jats:p>","DOI":"10.1371\/journal.pntd.0009636","type":"journal-article","created":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T17:33:18Z","timestamp":1627320798000},"page":"e0009636","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":14,"title":["In vitro activity of SPR719 against Mycobacterium ulcerans, Mycobacterium marinum and Mycobacterium chimaera"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1202-6614","authenticated-orcid":true,"given":"Sacha J.","family":"Pidot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica L.","family":"Porter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Troy","family":"Lister","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy P.","family":"Stinear","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2021,7,26]]},"reference":[{"key":"pntd.0009636.ref001","first-page":"11","article-title":"The Rise of Non-Tuberculosis Mycobacterial Lung Disease","author":"CN Ratnatunga","year":"2020","journal-title":"Front Immunol"},{"key":"pntd.0009636.ref002","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S1473-3099(06)70464-9","article-title":"Mycobacterium ulcerans infection: control, diagnosis, and treatment","volume":"6","author":"V Sizaire","year":"2006","journal-title":"Lancet Infect Dis"},{"key":"pntd.0009636.ref003","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/978-3-030-11114-4_2","volume-title":"Buruli Ulcer: Mycobacterium Ulcerans Disease","author":"EN Tabah","year":"2019"},{"key":"pntd.0009636.ref004","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s40475-018-0166-2","article-title":"Buruli Ulcer: a Review of the Current Knowledge","volume":"5","author":"RR Yotsu","year":"2018","journal-title":"Curr Trop Med Rep"},{"key":"pntd.0009636.ref005","first-page":"1","volume-title":"Buruli Ulcer: Mycobacterium Ulcerans Disease","author":"K R\u00f6ltgen","year":"2019"},{"key":"pntd.0009636.ref006","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/17512433.2020.1752663","article-title":"Pharmacologic management of Mycobacterium ulcerans infection","volume":"13","author":"TS van der Werf","year":"2020","journal-title":"Expert Rev Clin Pharmacol"},{"key":"pntd.0009636.ref007","first-page":"32","author":"C Franco-Paredes","year":"2018","journal-title":"Cutaneous Mycobacterial Infections. Clin Microbiol Rev"},{"key":"pntd.0009636.ref008","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1099\/ijs.0.02777-0","article-title":"Proposal to elevate the genetic variant MAC-A, included in the Mycobacterium avium complex, to species rank as Mycobacterium chimaera sp. nov","volume":"54","author":"E Tortoli","year":"2004","journal-title":"Int J Syt Evol Microbiol"},{"key":"pntd.0009636.ref009","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jinf.2019.12.007","article-title":"Long-term follow-up of post-cardiac surgery Mycobacterium chimaera infections: A 5-center case series","volume":"80","author":"KG Julian","year":"2020","journal-title":"J Infect"},{"key":"pntd.0009636.ref010","article-title":"Mycobacterium Chimaera: A Rare Presentation","volume":"10","author":"JA Miskoff","year":"2018","journal-title":"Cureus"},{"key":"pntd.0009636.ref011","doi-asserted-by":"crossref","first-page":"8792","DOI":"10.1021\/jm500563g","article-title":"Second-Generation Antibacterial Benzimidazole Ureas: Discovery of a Preclinical Candidate with Reduced Metabolic Liability","volume":"57","author":"A-L Grillot","year":"2014","journal-title":"J Med Chem"},{"key":"pntd.0009636.ref012","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1128\/AAC.04347-14","article-title":"A Novel Inhibitor of Gyrase B Is a Potent Drug Candidate for Treatment of Tuberculosis and Nontuberculosis Mycobacterial Infections","volume":"59","author":"CP Locher","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"pntd.0009636.ref013","article-title":"In Vitro Susceptibility Testing of a Novel Benzimidazole, SPR719, against Nontuberculous Mycobacteria","volume":"62","author":"BA Brown-Elliott","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"pntd.0009636.ref014","article-title":"Evaluating the Sterilizing Activity of SPR720 in Combination Therapy against Mycobacterium tuberculosis Infection in Mice","author":"C Shoen","year":"2019","journal-title":"Chicago"},{"key":"pntd.0009636.ref015","volume-title":"SPR720, A Novel Aminobenzimidazole Gyrase Inhibitor, Demonstrates Potent Efficacy Against Mycobacterium avium ATCC 700898 in a Chronic C3HeBFeJ Mouse Infection Model.","author":"D Verma","year":"2020"},{"key":"pntd.0009636.ref016","article-title":"Treatment of Mycobacterium Avium Subspecies Hominissuis (MAH) Infection with A Novel Gyrase Inhibitor (SPR719\/SPR720) Was Associated with A Significant Decrease in Bacterial Load As Assessed in Macrophages, Biofilm and in Mice","author":"LE Bermudez","year":"2018"},{"key":"pntd.0009636.ref017","volume-title":"Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes; Approved Standard\u2014Second Edition:","author":"CLSI","year":"2011"},{"key":"pntd.0009636.ref018","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1056\/NEJMc1612023","article-title":"Mycobacterium chimaera Spread from Heating and Cooling Units in Heart Surgery","volume":"376","author":"D Williamson","year":"2017","journal-title":"New Engl J Med"},{"key":"pntd.0009636.ref019","doi-asserted-by":"crossref","DOI":"10.1128\/genomeA.00963-17","article-title":"Complete Genome Sequence of Mycobacterium chimaera SJ42, a Nonoutbreak Strain from an Immunocompromised Patient with Pulmonary Disease","volume":"5","author":"NA Hasan","year":"2017","journal-title":"Genome Announc"},{"key":"pntd.0009636.ref020","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/jac\/dkr449","article-title":"Evaluation of gyrase B as a drug target in Mycobacterium tuberculosis","volume":"67","author":"S Chopra","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"pntd.0009636.ref021","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1128\/AAC.01751-13","article-title":"Optimization of Pyrrolamides as Mycobacterial GyrB ATPase Inhibitors: Structure-Activity Relationship and In Vivo Efficacy in a Mouse Model of Tuberculosis","volume":"58","author":"SH P","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"pntd.0009636.ref022","doi-asserted-by":"crossref","first-page":"5243","DOI":"10.1021\/jm800318d","article-title":"Novel Dual-Targeting Benzimidazole Urea Inhibitors of DNA Gyrase and Topoisomerase IV Possessing Potent Antibacterial Activity: Intelligent Design and Evolution through the Judicious Use of Structure-Guided Design and Stucture\u2212Activity Relationships","volume":"51","author":"PS Charifson","year":"2008","journal-title":"J Med Chem"},{"key":"pntd.0009636.ref023","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1128\/AAC.00596-06","article-title":"Dual Targeting of GyrB and ParE by a Novel Aminobenzimidazole Class of Antibacterial Compounds","volume":"51","author":"TH Grossman","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"pntd.0009636.ref024","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1128\/AAC.00685-12","article-title":"Activities of Moxifloxacin in Combination with Macrolides against Clinical Isolates of Mycobacterium abscessus and Mycobacterium massiliense","volume":"56","author":"G-E Choi","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"pntd.0009636.ref025","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1128\/AAC.00052-06","article-title":"In Vitro and In Vivo Activities of Rifampin, Streptomycin, Amikacin, Moxifloxacin, R207910, Linezolid, and PA-824 against Mycobacterium ulcerans","volume":"50","author":"B Ji","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"pntd.0009636.ref026","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/jac\/44.3.393","article-title":"Activity of moxifloxacin against mycobacteria","volume":"44","author":"SH Gillespie","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"pntd.0009636.ref027","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1021\/acsinfecdis.0c00025","article-title":"Advancement of GyrB Inhibitors for Treatment of Infections Caused by Mycobacterium tuberculosis and Non-tuberculous Mycobacteria","volume":"6","author":"SS Stokes","year":"2020","journal-title":"ACS Infect Dis"},{"key":"pntd.0009636.ref028","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/31159","article-title":"Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence","volume":"393","author":"ST Cole","year":"1998","journal-title":"Nature"},{"key":"pntd.0009636.ref029","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1038\/ng.477","article-title":"Comparative genomic and phylogeographic analysis of Mycobacterium leprae","volume":"41","author":"M Monot","year":"2009","journal-title":"Nat Genet"},{"key":"pntd.0009636.ref030","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1101\/gr.075069.107","article-title":"Insights from the complete genome sequence of Mycobacterium marinum on the evolution of Mycobacterium tuberculosis","volume":"18","author":"TP Stinear","year":"2008","journal-title":"Genome Res"},{"key":"pntd.0009636.ref031","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1101\/gr.5942807","article-title":"Reductive evolution and niche adaptation inferred from the genome of Mycobacterium ulcerans, the causative agent of Buruli ulcer","volume":"17","author":"TP Stinear","year":"2007","journal-title":"Genome Res"},{"key":"pntd.0009636.ref032","article-title":"Drug susceptibility distributions of Mycobacterium chimaera and other non-tuberculous mycobacteria","author":"B Schulthess","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"pntd.0009636.ref033","doi-asserted-by":"crossref","first-page":"e0006728","DOI":"10.1371\/journal.pntd.0006728","article-title":"Shorter-course treatment for Mycobacterium ulcerans disease with high-dose rifamycins and clofazimine in a mouse model of Buruli ulcer","volume":"12","author":"PJ Converse","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0009636.ref034","first-page":"63","article-title":"High-Dose Rifamycins Enable Shorter Oral Treatment in a Murine Model of Mycobacterium ulcerans Disease","author":"TF Omansen","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"pntd.0009636.ref035","doi-asserted-by":"crossref","first-page":"e0007857","DOI":"10.1371\/journal.pntd.0007857","article-title":"Telacebec (Q203)-containing intermittent oral regimens sterilized mice infected with Mycobacterium ulcerans after only 16 doses","volume":"14","author":"A Chauffour","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0009636.ref036","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00426-19","article-title":"Shortening Buruli Ulcer Treatment with Combination Therapy Targeting the Respiratory Chain and Exploiting Mycobacterium ulcerans Gene Decay","volume":"63","author":"PJ Converse","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"pntd.0009636.ref037","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00727-20","article-title":"Toward a Single-Dose Cure for Buruli Ulcer","volume":"64","author":"SS Thomas","year":"2020","journal-title":"Antimicrob Agents Chemother"}],"updated-by":[{"DOI":"10.1371\/journal.pntd.0009636","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T00:00:00Z","timestamp":1628121600000}}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0009636","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T18:14:38Z","timestamp":1628187278000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0009636"}},"subtitle":[],"editor":[{"given":"Katharina","family":"R\u00f6ltgen","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,7,26]]},"references-count":37,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0009636","relation":{"new_version":[{"id-type":"doi","id":"10.1371\/journal.pntd.0009636","asserted-by":"object"}]},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,26]]}}}